Katharine Orf

Katharine Orf

Auto-generated profile, based on publicly available information

Katharine Orf

Institute of Immunity & Transplantation, University College London, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
KOKatharine Orf
Katharine Orf
SRSrdan Rogosic
Srdan Rogosic
DDDaniel Dexter
Daniel Dexter
PAPhil Ancliff
Phil Ancliff
SBSaket Badle
Saket Badle
JBJack Bartram
Jack Bartram

25 September 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JMJaneth Mtenga
Janeth Mtenga
KOKate Orf
Kate Orf
JZJiexin Zheng
Jiexin Zheng
CCClara Chamba
Clara Chamba
HCHarrison Chuwa
Harrison Chuwa
JMJulie Makani
Julie Makani

1 October 2020 in Clinical Immunology
Verified
Journal Article
Closed access
KOKate Orf
Kate Orf
AAAhmed Abbas
Ahmed Abbas
KAKhaled Abdel-Aziz
Khaled Abdel-Aziz
SBSiobhan O. Burns
Siobhan O. Burns

12 November 2026 in Blood
Verified
Journal Article
Open access
RTRobert Torrance
Robert Torrance
KOKatharine Orf
Katharine Orf
NWNathan White
Nathan White
CMChristoph Matti
Christoph Matti
AMAlexander J. McKenna
Alexander J. McKenna
EMEmma C. Morris
Emma C. Morris
Germ line gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections, and an increased risk of malignancy. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) is curative but is associated with increased risk of morbidity and mortality in patients with STAT1 GOF mutations compared with those with other IEIs. To develop a curative, autologous alternative to HSCT, we evaluated gene-editing strategies in STAT1 GOF model cell lines, primary T cells, and patient-derived HSCs. Universal and mutation-specific strategies using CRISPR/Cas-mediated homology-directed repair were limited by low efficacy (<25%), poor viability, and a lack of allele specificity. In contrast, adenine base editing corrected the recurrent and highly pathogenic p.T385M mutation with upwards of 90% efficiency in patient T cells and HSCs without significant unintended on- or off-target genomic aberrations. Gene editing functionally restored total STAT1 expression (P< .0217), STAT1 phosphorylation (P< .0056), interferon-stimulated gene expression (OAS1; P = .0005), and improved interleukin-17 production (P< .0001). Edited HSCs retained multilineage differentiation capacity and sustained engraftment with persistence of the corrected allele at 16 weeks in humanized immunodeficient mice. These data demonstrate efficient and precise correction of STAT1 GOF mutations by base editing, with maintenance of the correction through long-term engraftment in vivo. To our knowledge, this represents the first application of gene editing to correct a dominant GOF mutation causing immunodeficiency, with potential applicability to other genetic disorders associated with heterozygous and GOF mutations.

10 July 2026 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
KOKatharine Orf
Katharine Orf
HYHannah Al Yousuf
Hannah Al Yousuf
TFThomas A. Fox
Thomas A. Fox
NSNadhira Samsudeen
Nadhira Samsudeen
SESuzanne Elcombe
Suzanne Elcombe
EMEmma C. Morris
Emma C. Morris

20 November 2026 in Blood Advances
Verified
Journal Article
Open access
KOKatharine Orf
Katharine Orf
RTRobert Torrance
Robert Torrance
CMChristoph Matti
Christoph Matti
NWNathan White
Nathan White
LTLeqi Tang
Leqi Tang
EMEmma C. Morris
Emma C. Morris
Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS1, APDS2) are rare gain-of-function inborn errors of immunity (IEI) leading to recurrent severe infections, bronchiectasis, lymphoproliferation and lymphoma. APDS1 and APDS2 are caused by mutations in PIK3CD and PIK3R1 respectively, which together encode the subunits of the phosphoinositide 3-kinase  enzyme (PI3K). The only curative therapy is allogeneic hematopoietic stem cell transplantation (alloHSCT), which requires a suitable donor and incurs a significant risk of morbidity and mortality. An adenine base editing strategy was developed to target the most frequent point mutations in APDS1 (p.E1021K, c.3061G>A; ~90% of patients) and APDS2 (c.1425+1G > A; ~50% of patients). Highly efficient correction of the pathogenic point mutation was achieved in patient T cells and hematopoietic stem cells (HSCs) and associated with functional restoration of PI3K signaling, rescue of the activation-induced cell death phenotype and, in APDS2, abrogated expression of the pathogenic splice isoform. Edited HSCs maintained pluripotency and achieved long-term engraftment in immunodeficient mice. A healthy control:APDS1 mixed chimera mouse model suggested that 75% wild-type engraftment generated a wild-type phenotype with respect to T and B cell dysfunction and lymphoproliferation, and thus similar editing efficiencies would be predicted to improve patient clinical phenotype. Together, these data demonstrate successful application of base editing to a gain-of-function IEI, with potential for application in other diseases.